Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016

Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and EGFR and ALK status are well-established markers for determining treatment in non-small-cell lung cancer (NSCLC). Treatment of ovarian cancer has only recently begun to benefit from this trend, but the role of biomarkers will continue to evolve in all three indications.

Contact sales account_box

Report

Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…

north_east

Report

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

north_east

Report

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

north_east

Report

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

north_east

Product logins

Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer | Access and Reimbursement | Realizing the Potential of Personalized Medicine in Oncology | US | 2016

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Follow us

Contact us